CYSTIC FIBROSIS IRT NEONATAL SCREEN

image not found

NABL Cap Accredited 
The Cystic Fibrosis IRT Neonatal Screen measures immunoreactive trypsinogen (IRT) in newborns to identify those at risk of cystic fibrosis at the earliest stage. Metropolis Healthcare performs this screening using highly sensitive assays to ensure timely and accurate detection. Early identification allows prompt diagnostic follow-up and early treatment, significantly improving long-term outcomes. When interpreted with confirmatory testing, it supports effective newborn health management.

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 470.00

Sample Type: Dried blood spot

Fasting Not Required


Notes: C0219

Frequently Asked Questions (FAQ's):

What does the IRT neonatal screen include at Metropolis Healthcare?
It includes measurement of immunoreactive trypsinogen levels from a newborn sample.

How does Metropolis Healthcare perform this screen?
Metropolis Healthcare uses sensitive and validated screening assays with strict quality controls.

Why is this screening important?
It helps detect cystic fibrosis early, allowing timely intervention and better health outcomes.

Who should undergo this screening at Metropolis Healthcare?
All newborns as part of routine newborn screening or as advised by clinicians.

Do I need special preparation for this test?
No special preparation is required; the test uses a standard newborn screening sample.

What happens if IRT levels are high?
Metropolis Healthcare advises confirmatory genetic testing and clinical evaluation.

How soon can results be expected from Metropolis Healthcare?
Results are typically available within the standard neonatal screening turnaround time.

Is this test a definitive diagnosis at Metropolis Healthcare?
No, it is a screening test; high results require further diagnostic testing.

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab